Details of the SBP
| General Information of Synthetic Binding Protein (SBP) (ID: SBP000146) | ||||||
|---|---|---|---|---|---|---|
| SBP Name |
BiTE AMG-427
|
|||||
| Synonyms |
AMG427; FLT3 BiTE?; FLT3 HLE BITE
|
|||||
| Design Method | Traditional methods (Site-directed mutagenesis and/or Directed evolution) | |||||
| Highest Status | Phase I | |||||
| Protein Scaffold Information of This SBP | ||||||
|---|---|---|---|---|---|---|
| Scaffold ID | PS018 | [1] , [2] | ||||
| Scaffold Name | BiTE | |||||
| Scaffold Class | Antibody fragment | |||||
| Fold Type | Beta-Sheets + Loops | |||||
| Binding Target(s) of This SBP (BTS) |
|---|
| BTS Name | Details | Mechanism | Application | Affinity | Research Organization | Ref |
|---|---|---|---|---|---|---|
| T-cell surface glycoprotein CD3 | Inhibitor | Acute myeloid leukaemia [ICD-11: XH8AA5] | N.A. | Amgen; Ludwig Maximilian Munich University | [1] , [2] | |
| Fms-related tyrosine kinase 3 ligand | Inhibitor | Acute myeloid leukaemia [ICD-11: XH8AA5] | N.A. | Amgen; Ludwig Maximilian Munich University | [1] , [2] | |
| Clinical Trial Information of This SBP | ||||||
|---|---|---|---|---|---|---|
| NCT03541369 | Click to show the Detail | |||||
| Indication | Relapsed or Refractory Acute Myeloid Leukemia | |||||
| Phase | Phase I | |||||
| Title | A Phase I First-In-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of?AMG 427?in Subjects With Relapsed/Refractory Acute Myeloid Leukemia. | |||||
| Status | Recruiting | |||||
| Sponsor | Amgen | |||||